Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q10589

UPID:
BST2_HUMAN

ALTERNATIVE NAMES:
HM1.24 antigen; Tetherin

ALTERNATIVE UPACC:
Q10589; A8K4Y4; Q53G07

BACKGROUND:
The protein Bone marrow stromal antigen 2, known alternatively as Tetherin, plays a crucial role in antiviral defense mechanisms. It effectively restricts the spread of enveloped viruses by tethering them to the cell membrane, impacting viruses from the Retroviridae, Flaviviridae, and Coronaviridae families, among others. Tetherin's actions extend beyond viral restriction; it influences cell growth, migration, and the immune system's response to viral infections through various signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Bone marrow stromal antigen 2 offers a pathway to innovative therapeutic approaches. Its unique mechanism of action against a broad spectrum of viruses and its regulatory role in immune signaling present valuable opportunities for the development of novel antiviral therapies and immune-modulating treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.